Immunocore Holdings plc
Immunocore Holdings plc (IMCR) Revenue
Annual & quarterly revenue history · segment & region breakdown
IMCR · revenue · updated Jun 15, 2026
Core revenue metrics
Trailing 12 monthsImmunocore Holdings plc trailing twelve-month (TTM) revenue is $0.39B, an increase of 20.00% year-over-year from $0.30B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.30B | +$0.05B | +20.00% |
| 2024-12-31 | $0.25B | +$0.05B | +25.63% |
| 2023-12-31 | $0.20B | +$0.05B | +36.85% |
| 2022-12-31 | $0.14B | +$0.12B | +433.32% |
| 2021-12-31 | $0.03B | -$0.00B | -10.19% |
| 2020-12-31 | $0.03B | +$0.00B | +17.32% |
| 2019-12-31 | $0.03B | +$0.00B | +8.52% |
| 2018-12-31 | $0.02B | +$0.01B | +63.74% |
| 2017-12-31 | $0.01B | -$0.00B | -12.25% |
| 2016-12-31 | $0.02B | +$0.01B | +43.69% |
Compare revenue vs peers
BiotechnologyCompare IMCR revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Immunocore Holdings plc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Immunocore Holdings plc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Immunocore Holdings plc's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IMCR revenue · 4 questionsIMCR's trailing twelve-month (TTM) revenue is $0.39B. That is an increase of 20.00% year-over-year from $0.30B in FY2025.
▸ Source: FMP · Immunocore Holdings plc SEC filings · GAAP · Immunocore Holdings plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026